Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week

Analysts also raised their price targets on the company. On top of that, it launched a new round of capital raising.

The Motley Fool • Aug 21, 2026

AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win

Amylyx surges after avexitide cuts hypoglycemic events 55% in phase III LUCIDITY study, paving the way for an FDA filing by end-2026 in PBH.

Zacks Investment Research • Aug 19, 2026

Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public offering price of $35.50 per share. In addition, Amylyx has granted the underwriters a 30-day option to purchase up to an additional 2,113,500 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the sh.

Business Wire • Aug 20, 2026

Amylyx drug cuts low blood sugar episodes in bariatric surgery patients in key trial

Amylyx Pharmaceuticals said on Tuesday its experimental drug met its main goal in a late-stage trial for post-bariatric ​hypoglycemia, a condition marked by dangerously low blood sugar ‌levels following weight-loss surgery.

Reuters • Aug 18, 2026

Why Amylyx Pharmaceuticals Stock Skyrocketed Today

Amylyx is developing a GLP-1 treatment for people with chronic low blood sugar. The experimental therapy displayed a favorable safety profile in a clinical study.

The Motley Fool • Aug 18, 2026

A New Use for GLP-1s? Amylyx Pharma Catapults To 3-Year High.

Amylyx stock skyrocketed Tuesday after its GLP-1 drug reduced hypoglycemia in patients who've undergone bariatric surgery.

Investors Business Daily • Aug 18, 2026

Amylyx stock soars on GLP-1 success: here's why investors should sell

Amylyx Pharmaceuticals (AMLX) shares exploded to the upside on August 18th after the company reported blockbuster topline results from its pivotal Phase 3 LUCIDITY trial. The late-stage study evaluated avexitide – the pharmaceutical firm's first-in-class GLP-1 receptor antagonist – in patients suffering from post-bariatric hypoglycemia (PBH).

Invezz • Aug 18, 2026

Amylyx Phase III Avexitide Trial Cuts Severe Hypoglycemic Events 55%

Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III LUCIDITY trial of avexitide met its primary endpoint, reducing the composite rate of clinically significant hypoglycemic events by 55% versus placebo in adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery.

MarketBeat • Aug 18, 2026

Amylyx Pharmaceuticals Comes Closer to Potentially Delivering First Treatment for Weight Loss Surgery-Related Low Suger Level

Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) stock is trading higher on Tuesday after the company released highly favorable topline data from its Phase 3 LUCIDITY clinical trial.

Benzinga • Aug 18, 2026

Amylyx Pharmaceuticals, Inc. (AMLX) Discusses Positive Phase III LUCIDITY Topline Results for Avexitide in Post-Bariatric Hypoglycemia Transcript

Amylyx Pharmaceuticals, Inc. (AMLX) Discusses Positive Phase III LUCIDITY Topline Results for Avexitide in Post-Bariatric Hypoglycemia Transcript

Seeking Alpha • Aug 18, 2026